tiprankstipranks
Trending News
More News >
Altamira Therapeutics (CYTOF)
OTHER OTC:CYTOF
US Market
Advertisement

Altamira Therapeutics (CYTOF) Price & Analysis

Compare
599 Followers

CYTOF Stock Chart & Stats


Altamira Therapeutics News

CYTOF FAQ

What was Altamira Therapeutics’s price range in the past 12 months?
Altamira Therapeutics lowest stock price was $0.05 and its highest was $0.66 in the past 12 months.
    What is Altamira Therapeutics’s market cap?
    Altamira Therapeutics’s market cap is $342.93K.
      When is Altamira Therapeutics’s upcoming earnings report date?
      Altamira Therapeutics’s upcoming earnings report date is Apr 15, 2026 which is in 195 days.
        How were Altamira Therapeutics’s earnings last quarter?
        Altamira Therapeutics released its earnings results on Aug 29, 2025. The company reported -$0.306 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.306.
          Is Altamira Therapeutics overvalued?
          According to Wall Street analysts Altamira Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Altamira Therapeutics pay dividends?
            Altamira Therapeutics does not currently pay dividends.
            What is Altamira Therapeutics’s EPS estimate?
            Altamira Therapeutics’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Altamira Therapeutics have?
            Altamira Therapeutics has 5,715,472 shares outstanding.
              What happened to Altamira Therapeutics’s price movement after its last earnings report?
              Altamira Therapeutics reported an EPS of -$0.306 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Altamira Therapeutics?
                Currently, no hedge funds are holding shares in CYTOF

                Company Description

                Altamira Therapeutics

                Altamira Therapeutics (CYTO) is a biopharmaceutical company focused on developing and commercializing RNA-based therapeutics. The company operates in the biotechnology sector, leveraging its proprietary technology platforms to create innovative treatments for various diseases, including inner ear disorders, nasal and allergy conditions, and other RNA-targeted therapies. Altamira aims to address unmet medical needs by advancing its pipeline of novel products through clinical development and regulatory approval.

                Altamira Therapeutics (CYTOF) Earnings & Revenues

                CYTOF Earnings Call

                Q2 2025
                0:00 / 0:00
                Earnings Call Sentiment|Neutral
                Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.View all CYTOF earnings summaries
                Similar Stocks
                Company
                Price & Change
                Follow
                Biodexa Pharmaceuticals
                Q/C Technologies
                Salarius Pharmaceuticals
                Scinai Immunotherapeutics
                Oragenics

                Ownership Overview

                0.06%<0.01%100.00%
                Insiders
                <0.01% Other Institutional Investors
                100.00% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis